Lablytica is a company specialising in bioanalytical services including sample analysis in plasma, tissue samples and urine. The research and development activities carried out at our facility in Uppsala, Sweden, are fully compliant with Good Laboratory Practice (GLP) and relevant regulatory guidelines from the EMA and the FDA. The laboratory is also part of the Swedish OECD GLP regulatory inspection program from SWEDAC.
At Lablytica they offer:
- Bioanalytical services for qualitative and quantitative drug and metabolite analysis.
- Method development for bioanalysis, or method transfer for existing methods, followed by validation in line with FDA and EMA guidelines.
- Bioanalysis of biomarkers.
- GLP support for pre-clinical studies with small sample volumes.
- Bioanalytical support for clinical studies, such as dose escalation studies (SAD and MAD), with short turnaround times as well as for clinical studies with large sample numbers such as bio-equivalency and bioavailability studies.
- Dosing solution analysis for GLP studies .
- Fully automated 96-well sample processing and analysis.
- Cutting edge technology with automated and analytical instrumentation, including high sensitivity and specificity with LC-MS/MS.
- Synthesis and use of stable-isotope-labelled internal standards.
Lablytica is a spin-off company from Recipharm OT Chemistry in Uppsala, Sweden. The team consists of 8 dedicated analytical chemists.
Since 2016, Lablytica has been part of the SWEDAC GLP inspection program for the performance of GLP analytical study phases. In November 2019, they became an independent company owned by the holding company Center for Translational Research (CTR).